Burinex (Bumetanide)
Potent loop diuretic injection for rapid treatment of edema in heart failure, liver cirrhosis and kidney disease
Quick facts about Burinex
Key takeaways about Burinex
- Potent loop diuretic for rapid fluid removal: Bumetanide is approximately 40 times more potent than furosemide, making Burinex injection effective when urgent diuresis is needed in hospital settings
- Fast-acting when given intravenously: Onset of action within 2–5 minutes of IV injection, with peak effect at 15–30 minutes and duration of 2–3 hours
- Regular electrolyte monitoring is essential: Bumetanide can cause significant electrolyte disturbances including low potassium, sodium, and chloride, which may lead to dangerous cardiac arrhythmias if uncorrected
- Not recommended for children: Due to insufficient safety data, Burinex should not be used in pediatric patients
- Caution with ototoxic drugs: Combining Burinex with aminoglycoside antibiotics or other ototoxic medications may increase the risk of hearing damage, particularly at high doses or in patients with impaired kidney function
What Is Burinex and What Is It Used For?
Burinex is a potent loop diuretic (water pill) containing bumetanide, administered by injection to accelerate the excretion of urine. It is used in adults to treat edema (fluid retention in the body) that occurs in connection with heart failure, liver cirrhosis, or kidney disease. Burinex injection is typically used in hospital settings when rapid diuresis is required or when oral medication is not feasible.
Bumetanide belongs to a class of medications known as loop diuretics or high-ceiling diuretics. These drugs act on the thick ascending limb of the loop of Henle in the kidneys, where they inhibit the sodium-potassium-chloride co-transporter (NKCC2). By blocking this transporter, bumetanide prevents the reabsorption of sodium, potassium, and chloride ions from the tubular fluid back into the bloodstream. This leads to increased excretion of water and electrolytes in the urine, effectively reducing the volume of fluid in the body.
The pharmacological profile of bumetanide is notable for its exceptional potency compared to other loop diuretics. On a milligram-for-milligram basis, bumetanide is approximately 40 times more potent than furosemide, the most commonly prescribed loop diuretic. This means that 1 mg of bumetanide produces a diuretic effect roughly equivalent to 40 mg of furosemide. Additionally, bumetanide has more predictable oral bioavailability (approximately 80–95%) compared to furosemide (40–70%), which can be an important clinical advantage in patients with gut edema from heart failure, where drug absorption may be impaired.
When administered intravenously, Burinex works extremely rapidly. The diuretic effect begins within 2–5 minutes of injection, reaches its peak at approximately 15–30 minutes, and typically lasts 2–3 hours. When given as an intramuscular injection, the onset of action is slightly delayed, usually occurring within 30–40 minutes. This rapid onset makes Burinex injection particularly valuable in acute clinical situations such as acute pulmonary edema, where immediate fluid removal is critical, and acute decompensated heart failure, where rapid symptom relief can be life-saving.
Burinex is approved and prescribed for the following conditions in adults:
- Congestive heart failure: When the heart is unable to pump blood efficiently, fluid accumulates in the lungs (pulmonary edema) and peripheral tissues (peripheral edema). Burinex rapidly removes excess fluid, relieving breathlessness and swelling
- Liver cirrhosis with ascites: Advanced liver disease often leads to fluid accumulation in the abdominal cavity (ascites) due to portal hypertension and reduced albumin production. Bumetanide helps manage this fluid overload, often in combination with spironolactone
- Kidney disease: Conditions such as nephrotic syndrome can cause significant edema due to protein loss in the urine. Bumetanide is used when other diuretics have proven insufficient or when rapid diuresis is clinically necessary
Bumetanide may also be used for other conditions not specifically listed in the standard product information. Your healthcare provider will determine whether Burinex is appropriate for your specific situation. Always follow the instructions given by your treating physician and do not self-administer this medication.
Burinex injection is administered by healthcare professionals in clinical settings. It is given either as an intravenous injection (into a vein) or an intramuscular injection (into a muscle). The dosage and method of administration are determined by your doctor based on your individual medical needs and the severity of your condition. This medication is not intended for self-administration at home.
What Should You Know Before Using Burinex?
Before receiving Burinex, your doctor must assess your kidney function, electrolyte levels, blood pressure, and all other medications you take. Burinex must not be used in several specific situations, including severe liver impairment with encephalopathy, kidney failure with absent urine production, and pre-existing severe electrolyte imbalances. Regular blood monitoring is essential throughout treatment.
Loop diuretics such as bumetanide are powerful medications that can cause significant shifts in fluid and electrolyte balance. For this reason, a thorough medical assessment is required before treatment begins. Your doctor will typically order blood tests to evaluate your kidney function, liver function, electrolyte levels (including potassium, sodium, chloride, and magnesium), blood sugar, and uric acid levels before initiating Burinex therapy.
Contraindications
Burinex must not be used in the following situations:
- Allergy to bumetanide, formaldehyde, or any other ingredient in the formulation (see the ingredients section for a complete list of excipients)
- Severe liver impairment with hepatic encephalopathy: A condition where liver dysfunction leads to accumulation of toxins that affect brain function. Diuretic-induced electrolyte changes can worsen this dangerous condition
- Kidney failure with little or no urine production (anuria): When the kidneys are no longer producing urine, diuretics cannot exert their intended effect and may cause further harm
- Pre-existing severe electrolyte imbalances: Conditions with significantly altered fluid and salt balance in the body, as bumetanide would exacerbate these disturbances
If you have a history of sulfonamide hypersensitivity, there may be a cross-reactivity risk with bumetanide, as loop diuretics contain a sulfonamide moiety. While true cross-reactivity is considered rare, your doctor should be informed of any previous allergic reactions to sulfonamide-containing medications, including certain antibiotics and other loop diuretics.
Serious skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with bumetanide. Stop using Burinex immediately and seek emergency medical care if you develop: reddish, non-raised, target-like patches on the trunk; skin peeling; blistering; or sores in the mouth, throat, nose, genitals, or eyes. These serious skin reactions may be preceded by fever and flu-like symptoms.
Warnings and Precautions
Talk to your doctor or pharmacist before receiving Burinex if any of the following apply to you:
- Previous severe skin reactions: If you have ever experienced serious skin rash, skin peeling, blistering, or mouth sores after taking bumetanide, other loop diuretics, or sulfonamides
- Formaldehyde sensitivity: The injection contains very small amounts of formaldehyde. Caution is required due to the risk of developing a severe allergic reaction (anaphylaxis)
- Significantly impaired liver function: Dose reduction and more frequent monitoring may be necessary
- Low blood pressure (hypotension): Bumetanide can lower blood pressure further, potentially causing dizziness, fainting, or falls
- Low magnesium levels (hypomagnesemia): Bumetanide can worsen magnesium depletion, which may increase the risk of cardiac arrhythmias
- Urinary tract obstruction: Narrowing or blockage of the urinary tract may be exacerbated by the increased urine flow caused by diuretics
- Significantly impaired kidney function: Including elevated blood urea or creatinine levels, requiring careful dose adjustment and monitoring
- Diabetes mellitus: Blood and urine glucose should be regularly monitored, as bumetanide can affect blood sugar levels
Your doctor will regularly check your blood electrolyte concentrations throughout treatment, as Burinex can alter the fluid and salt balance in the body. This monitoring is particularly important for patients who are elderly, have impaired kidney or liver function, or are taking multiple medications that affect electrolyte levels.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving Burinex.
- Pregnancy: Bumetanide should not be used during pregnancy unless the doctor considers it absolutely necessary. It should only be used in pregnant women with heart failure when the benefits of treatment clearly outweigh the risks to the fetus. Diuretics can reduce placental perfusion and potentially affect fetal development
- Breastfeeding: Burinex must not be used during breastfeeding. Bumetanide may pass into breast milk and could affect the nursing infant. If diuretic treatment is essential, your doctor will advise on alternative feeding methods
Driving and Operating Machinery
Dizziness may occur during treatment with Burinex, and this should be taken into account when driving or operating machinery. You are personally responsible for assessing whether you are fit to drive or perform tasks that require alertness. Do not drive or operate heavy machinery if you experience dizziness, lightheadedness, or blurred vision during treatment.
Use in Children
Burinex is not recommended for use in children due to insufficient information on safety, efficacy, and appropriate dosing in the pediatric population. Alternative diuretics with better-established pediatric safety profiles should be considered for children who require diuretic therapy.
How Does Burinex Interact with Other Drugs?
Burinex interacts with many commonly prescribed medications. The most clinically significant interactions involve cardiac glycosides (such as digoxin), where bumetanide-induced low potassium can increase toxicity risk, and aminoglycoside antibiotics, where the combination may increase the risk of hearing damage. Always tell your healthcare provider about all medications you are taking.
Drug interactions with bumetanide can range from clinically manageable to potentially dangerous. The most important interactions relate to electrolyte disturbances (especially potassium depletion), additive hypotensive effects, nephrotoxicity, and ototoxicity. Because Burinex is typically administered in hospital settings, your healthcare team will monitor for these interactions carefully. Below is a comprehensive overview of the key drug interactions organized by clinical significance.
Major Interactions
The following drug interactions are considered clinically significant and may require dose adjustments, close monitoring, or avoidance of the combination:
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Cardiac glycosides (e.g. digoxin) | Bumetanide-induced hypokalemia increases the risk of digoxin toxicity, which can cause life-threatening cardiac arrhythmias | Monitor potassium levels closely; potassium supplementation may be required |
| Aminoglycoside antibiotics (e.g. gentamicin, tobramycin) | Additive ototoxicity (hearing damage) and nephrotoxicity (kidney damage) | Avoid concurrent use if possible; if combination is necessary, monitor hearing and renal function closely |
| Lithium | Bumetanide reduces lithium excretion, leading to increased lithium blood levels and risk of toxicity | Monitor lithium levels; dose reduction of lithium may be necessary |
| Antiarrhythmic agents | Electrolyte disturbances from bumetanide (especially low potassium and magnesium) increase the risk of cardiac arrhythmias | Monitor electrolytes and ECG; correct any electrolyte imbalances promptly |
| Cephalosporin antibiotics | Increased risk of nephrotoxicity when combined with potent loop diuretics | Monitor renal function; use the lowest effective diuretic dose |
Moderate Interactions
The following interactions are clinically relevant and usually require monitoring or minor dose adjustments:
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| NSAIDs (e.g. ibuprofen, naproxen) | NSAIDs can reduce the diuretic and antihypertensive effect of bumetanide by inhibiting prostaglandin synthesis in the kidneys | Monitor urine output and blood pressure; higher diuretic doses may be needed |
| Other diuretics | Additive diuretic effect increasing the risk of dehydration and electrolyte depletion | Careful dose titration; frequent electrolyte and fluid balance monitoring |
| Antihypertensive agents | Additive blood pressure-lowering effect, increasing risk of hypotension and dizziness | Monitor blood pressure; dose adjustments may be needed |
| Tricyclic antidepressants | May potentiate the blood pressure-lowering effect of bumetanide | Monitor blood pressure when initiating or adjusting either medication |
| Probenecid (antigout agent) | Probenecid may reduce the diuretic effect of bumetanide by competing for renal tubular secretion | Higher doses of bumetanide may be required; monitor diuretic response |
| Potassium-lowering agents | Additive potassium depletion, increasing the risk of hypokalemia | Monitor potassium levels; supplementation may be necessary |
What Is the Correct Dosage of Burinex?
Burinex injection is administered by healthcare professionals. The dosage is individualized based on the patient's condition, kidney function, and clinical response. It is given as an intravenous (IV) or intramuscular (IM) injection. Each ampoule contains 4 ml of solution at a concentration of 0.5 mg/ml (2 mg bumetanide per ampoule).
The dosage and route of administration of Burinex are determined by the prescribing physician based on the individual patient's needs, the severity of fluid retention, underlying medical conditions, and renal function. Because Burinex is a hospital-administered medication, patients do not need to calculate their own doses. However, understanding the general dosing principles can help patients be more informed about their treatment.
Adults
Intravenous (IV) Administration
The usual initial dose is 0.5–1 mg (1–2 ml) given as a slow intravenous injection. If the response is inadequate, additional doses may be given at intervals of 2–3 hours. For continuous intravenous infusion, the typical dose range is 1–5 mg over 24 hours, adjusted according to clinical response and electrolyte monitoring. In acute pulmonary edema, a higher initial dose of 1–2 mg may be used to achieve rapid symptom relief.
Intramuscular (IM) Administration
When intravenous access is not available or not feasible, Burinex may be given as an intramuscular injection. The dosage is the same as for intravenous use, but the onset of action is slightly slower (approximately 30–40 minutes compared to 2–5 minutes for IV). The intramuscular route is less commonly used in acute situations due to the delayed onset.
Dose Adjustment in Kidney Impairment
Patients with significantly impaired kidney function may require higher doses to achieve an adequate diuretic response, as reduced glomerular filtration limits the amount of bumetanide reaching its site of action. However, higher doses also increase the risk of ototoxicity and electrolyte disturbances, so careful dose titration with close monitoring is essential. Your doctor will balance the need for effective diuresis against the risk of adverse effects.
Children
Burinex is not recommended for use in children. There is insufficient data on the safety, efficacy, and appropriate dosing of bumetanide in the pediatric population. Children requiring diuretic therapy should be treated with alternative medications that have established pediatric dosing guidelines, such as furosemide.
Elderly Patients
Elderly patients may be more susceptible to the effects of diuretics, including excessive diuresis, dehydration, electrolyte imbalances, and hypotension. Lower initial doses and more gradual dose titration are generally recommended. Renal function should be assessed before and during treatment, as age-related decline in kidney function may affect drug clearance and response.
Missed Dose
Since Burinex is administered by healthcare professionals in a clinical setting, the risk of a missed dose is minimal. Your medical team will ensure that doses are given according to the prescribed schedule. If you have concerns about the timing of your doses, speak with your nurse or doctor.
Overdose
Overdose with bumetanide can cause severe dehydration, excessive urine production, and dangerous electrolyte disturbances. If you suspect that an overdose has occurred, contact emergency services immediately.
Symptoms of bumetanide overdose may include:
- Dry mouth, extreme thirst, and dehydration
- Weakness, drowsiness, confusion, and restlessness
- Nausea, vomiting, and abdominal pain
- Muscle pain, cramps, and seizures
- Low blood pressure, rapid heart rate, and dizziness
- Significantly increased urine production
Treatment of overdose is supportive and includes fluid and electrolyte replacement based on blood test results. There is no specific antidote for bumetanide overdose.
What Are the Side Effects of Burinex?
Like all medicines, Burinex can cause side effects, although not everyone will experience them. The most common side effects include electrolyte disturbances (changes in potassium, sodium, and chloride levels), dizziness, tiredness, headache, and abdominal discomfort. Some side effects can be serious and require immediate medical attention.
Side effects of bumetanide are largely related to its potent diuretic action and the resulting changes in fluid and electrolyte balance. The risk and severity of side effects depend on the dose, duration of treatment, the patient's overall health, kidney and liver function, and concurrent medications. Regular monitoring of blood electrolytes, kidney function, and clinical status helps detect and manage side effects early.
Reddish, non-raised, target-like spots on the trunk, skin peeling, blistering, or sores in the mouth, throat, nose, genitals, or eyes — these may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis, which are rare but life-threatening skin reactions. Also seek urgent care if you develop signs of infection (fever with severely impaired general condition, sore throat, difficulty urinating) — as bumetanide can rarely affect white blood cell counts (agranulocytosis).
Common Side Effects
May affect up to 1 in 10 users
- Electrolyte disturbances: low levels of potassium (hypokalemia), sodium (hyponatremia), and chloride (hypochloremia), or elevated potassium (hyperkalemia)
- Dizziness, tiredness, and headache
- Abdominal pain and nausea
- Muscle pain (myalgia)
- Urination problems
Uncommon Side Effects
May affect up to 1 in 100 users
- Elevated blood sugar (hyperglycemia)
- Elevated uric acid levels (hyperuricemia) and gout
- Fainting (syncope)
- Low blood pressure (hypotension)
- Vomiting, diarrhea, and constipation
- Skin reactions: rash, hives (urticaria), itching (pruritus), and increased sensitivity to light (photosensitivity)
- Reduced kidney function, including renal failure
Frequency Not Known
Reported cases; frequency cannot be estimated
- Decreased platelet count (thrombocytopenia) and anemia
- Hearing disturbances (ototoxicity), including tinnitus
- Skin inflammation (dermatitis) and eczema
- Dehydration
- Severe allergic reactions (anaphylaxis) — related to formaldehyde content
- Agranulocytosis (severe reduction in white blood cells)
If you experience any side effects, tell your doctor, nurse, or pharmacist. This includes any side effects not listed here. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should Burinex Be Stored?
Burinex injection should be stored below 25°C in the original outer carton to protect from light. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of pharmaceutical products is essential to maintain their safety and efficacy. Burinex injection, like all injectable medicines, must be stored according to specific conditions to ensure the medication remains stable and effective. In hospital settings, the pharmacy department is responsible for proper storage, but patients and caregivers should be aware of these requirements.
- Temperature: Store at or below 25°C (77°F). Do not freeze
- Light protection: Keep the ampoules in the outer carton to protect from light, as bumetanide solution is light-sensitive
- Child safety: Store out of the sight and reach of children at all times
- Expiry date: Do not use Burinex after the expiry date stated on the packaging after “EXP.” The expiry date refers to the last day of the stated month
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer used. These measures help protect the environment
Each ampoule of Burinex contains 4 ml of solution for injection. The product is supplied in packs of 5 ampoules × 4 ml. Once an ampoule has been opened, any unused solution should be discarded immediately, as the product does not contain preservatives. Do not use the solution if it appears discolored, cloudy, or contains visible particles.
What Does Burinex Contain?
The active substance in Burinex is bumetanide at a concentration of 0.5 mg/ml. Each 4 ml ampoule contains 2 mg of bumetanide. The inactive ingredients (excipients) are disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, xylitol, and water for injections.
Understanding the complete composition of a medication is important for identifying potential allergens or ingredients that may interact with other conditions. Burinex injection is a clear, colorless solution with the following composition:
Active Ingredient
- Bumetanide 0.5 mg/ml — The pharmacologically active substance responsible for the diuretic effect. Bumetanide is a sulfonamide-type loop diuretic that acts on the sodium-potassium-chloride co-transporter (NKCC2) in the ascending limb of the loop of Henle
Inactive Ingredients (Excipients)
- Disodium phosphate dihydrate — A buffering agent that helps maintain the pH of the solution within the appropriate range for injection
- Sodium dihydrogen phosphate dihydrate — A co-buffering agent used in combination with disodium phosphate to maintain solution stability and pH
- Xylitol — A sugar alcohol used as a tonicity agent to make the solution isotonic (same osmotic pressure as blood), reducing pain and tissue irritation at the injection site
- Water for injections — Highly purified water used as the solvent for the solution. It is prepared according to pharmacopoeial standards to be free from pyrogens and other contaminants
Note that the formulation may contain trace amounts of formaldehyde from the manufacturing process. Patients with known formaldehyde allergy should inform their healthcare provider before receiving this medication, as there is a risk of severe allergic reactions (anaphylaxis) in sensitized individuals.
Burinex injection is a clear, colorless solution supplied in glass ampoules. Each ampoule contains 4 ml of solution (2 mg bumetanide). Packs contain 5 ampoules. The solution should be visually inspected before use — do not use if discolored, cloudy, or if particles are visible.
Frequently Asked Questions About Burinex
Both Burinex (bumetanide) and furosemide (commonly known as Lasix) are loop diuretics that work by the same mechanism of action, inhibiting the NKCC2 transporter in the kidneys. The key differences are potency and bioavailability. Bumetanide is approximately 40 times more potent than furosemide on a weight-for-weight basis, meaning that 1 mg of bumetanide is roughly equivalent to 40 mg of furosemide. Additionally, bumetanide has more predictable oral bioavailability (80–95%) compared to furosemide (40–70%), which can be clinically significant in patients with gut edema from heart failure. Both medications share similar side effect profiles and drug interaction patterns. The choice between them is typically made by the treating physician based on the individual clinical situation.
Yes, ototoxicity (hearing damage) is a known potential side effect of loop diuretics, including bumetanide. This risk is dose-dependent and is greatest when high doses are given rapidly by intravenous injection, when the drug is combined with other ototoxic medications (such as aminoglycoside antibiotics like gentamicin), or in patients with impaired kidney function. Symptoms may include tinnitus (ringing in the ears), hearing loss, or a sensation of fullness in the ears. In most cases, bumetanide-induced hearing problems are reversible when the drug is discontinued or the dose is reduced. However, permanent hearing loss has been reported in rare cases, particularly with concurrent aminoglycoside use. If you notice any changes in your hearing during treatment, inform your healthcare team immediately.
Burinex injection is used in situations where rapid diuresis is needed or when oral medication is not feasible. Intravenous bumetanide has an onset of action within 2–5 minutes, compared to 30–60 minutes for oral forms. This makes the injection form essential in acute emergencies such as pulmonary edema, where immediate fluid removal from the lungs is critical. Additionally, patients who are critically ill, vomiting, unable to swallow, or have significant gut edema (which impairs oral drug absorption) may require the injectable form. In some countries, bumetanide is also available as oral tablets, but the Burinex brand in this formulation is specifically the injectable solution. Your doctor will switch you to oral medication when your clinical condition allows.
The diuretic effect of Burinex injection is rapid but relatively short-lived. When given intravenously, the effect begins within 2–5 minutes, peaks at approximately 15–30 minutes, and typically lasts 2–3 hours. For intramuscular injection, the onset is 30–40 minutes with a similar duration of action. This relatively short duration means that in clinical practice, repeat doses may be given at intervals of 2–3 hours, or the drug may be administered as a continuous intravenous infusion for sustained diuretic effect. The half-life of bumetanide in the blood is approximately 1–1.5 hours in patients with normal kidney function, but may be prolonged in patients with renal or hepatic impairment.
Because Burinex causes significant fluid and electrolyte loss, adequate fluid intake is important unless your doctor has specifically restricted your fluid intake (as is sometimes necessary in heart failure). Your healthcare team will monitor your fluid balance and electrolyte levels through blood tests. Potassium-rich foods such as bananas, oranges, potatoes, spinach, and tomatoes may be encouraged to help replace potassium lost through increased urination, unless you have been told otherwise. However, dietary recommendations should always be discussed with your healthcare team, as they depend on your individual blood test results and overall medical condition. In some cases, potassium supplements may be prescribed alongside Burinex treatment.
Bumetanide is not individually listed on the WHO Model List of Essential Medicines, though furosemide (another loop diuretic in the same drug class) is included. Both drugs work by the same pharmacological mechanism and are considered therapeutically equivalent when used at appropriate doses. The inclusion of furosemide on the WHO list reflects its wider global availability and lower cost rather than any difference in clinical efficacy. In many clinical settings, bumetanide is preferred over furosemide due to its more predictable bioavailability and higher potency, which can be advantageous in certain patient populations.
References & Medical Sources
All information in this article is based on international medical guidelines, peer-reviewed clinical research, and approved prescribing information. The following sources were used:
- McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012
- Felker GM, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure (DOSE trial). New England Journal of Medicine. 2011;364(9):797–805. doi:10.1056/NEJMoa1005419
- British National Formulary (BNF) — Bumetanide. National Institute for Health and Care Excellence (NICE). Updated 2024. bnf.nice.org.uk
- European Medicines Agency (EMA). Summary of Product Characteristics — Bumetanide. www.ema.europa.eu
- Brater DC. Pharmacology of Diuretics. American Journal of the Medical Sciences. 2000;319(1):38–50.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. 2023.
- Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. New England Journal of Medicine. 2017;377(20):1964–1975. doi:10.1056/NEJMra1703100
This article is based on evidence level 1A — the highest quality of medical evidence, derived from systematic reviews and meta-analyses of randomized controlled trials. All medical claims are evaluated using the GRADE framework. Content is reviewed according to guidelines from the European Society of Cardiology (ESC), American College of Cardiology (ACC), British National Formulary (BNF), and the World Health Organization (WHO).
About Our Medical Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in clinical pharmacology, cardiology, nephrology, and internal medicine. Our team follows strict editorial guidelines to ensure all content is evidence-based, clinically accurate, and accessible to patients and caregivers.
Writing Standards
All content follows the GRADE evidence framework and is based on peer-reviewed research, international clinical guidelines, and approved prescribing information. We declare no conflicts of interest and receive no pharmaceutical industry funding.
Review Process
Every article undergoes multi-stage review by medical specialists, pharmacists, and medical editors. Content is updated regularly to reflect the latest evidence and guideline changes. Last medical review: .